Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd as indicated in metadata) covers the quarter ended June 30, 2018, and the 12-month period ending on that date. The registrant is an Australian biotechnology entity subject to ASX Listing Rule 4.7B.
Key Financial Metrics
Cash Flow (Quarter Ended June 30, 2018):
- Operating Cash Flow: Net cash used in operating activities was $(2,597) thousand AUD.
- Investing Cash Flow: Net cash used in investing activities was $(33) thousand AUD.
- Financing Cash Flow: Net cash from financing activities was $0 thousand AUD.
- Net Increase in Cash: Cash and cash equivalents increased by $17,625 thousand AUD during the quarter, primarily driven by a significant adjustment in the reconciliation of cash balances.
- Cash Position: Cash and cash equivalents at the end of the quarter totaled $15,235 thousand AUD.
Operating Expenses (Quarter):
- Research and development: $(1,327) thousand AUD.
- Staff costs: $(895) thousand AUD.
- Administration and corporate costs: $(413) thousand AUD.
- Advertising and marketing: $(10) thousand AUD.
Revenue and Profit: The filing text does not provide a clear value for revenue or net profit, as the document focuses exclusively on cash flow activities.
Debt and Liquidity: No loan facilities or credit standby arrangements were drawn at quarter end. The company holds $9,235 thousand AUD in bank balances and $6,000 thousand AUD in call deposits.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period in narrative form. However, the cash flow statement indicates a net increase in cash of $17,625 thousand AUD for the quarter, contrasting with a net cash outflow from operations of $(2,597) thousand AUD. This discrepancy suggests significant non-operating adjustments or reclassifications in the cash reconciliation (Item 4.1 vs Item 4.6) which are not fully explained in the provided text.
Guidance, Outlook, and Risks
Estimated Cash Outflows (Next Quarter):
- Total estimated cash outflows: $4,015 thousand AUD.
- Research and development: $2,500 thousand AUD.
- Staff costs: $900 thousand AUD.
- Administration and corporate costs: $600 thousand AUD.
- Advertising and marketing: $15 thousand AUD.
Risks and Contingencies: The filing does not contain specific narrative disclosures regarding risks, contingencies, or unusual items beyond the standard quarterly reporting requirements.
Investor Verification Checklist
- Verify the discrepancy between the reported net increase in cash ($17,625k) and the sum of operating, investing, and financing cash flows, as the reconciliation details are not fully explicit in the text.
- Confirm the company name is Prana Biotechnology Limited, as the metadata reference to "Alteryx Therapeutics Ltd" appears incorrect based on the filing content.
- Review the composition of the $6,000 thousand AUD in call deposits to understand liquidity constraints.
- Monitor the burn rate against the estimated $4,015 thousand AUD outflow for the upcoming quarter.